Education
About Us
Working with TipRanks
Follow Us
PSIL - ETF AI Analysis
Top Page
AdvisorShares Psychedelics ETF (PSIL)
Rating:42Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several key holdings, such as ATAI Life Sciences and Neuphoria Therapeutics, have delivered strong year-to-date performance, supporting the ETF's overall returns.
Focused Sector Exposure
The ETF's heavy allocation to the health care sector allows investors to target a growing industry with potential for innovation in psychedelics.
Improving Short-Term Performance
The ETF has shown positive momentum over the past month and three months, indicating recent recovery or growth.
Negative Factors
High Expense Ratio
The ETF charges a relatively high expense ratio, which could eat into investor returns over time.
Sector Concentration Risk
With nearly all assets in the health care sector, the fund is highly exposed to risks specific to this industry.
Limited Geographic Diversification
The ETF is heavily concentrated in U.S. and Canadian companies, offering little exposure to other global markets.
PSIL vs. SPDR S&P 500 ETF (SPY)
AUM19.64M
RegionGlobal
Expense Ratio1.00%
Beta0.91
IssuerAdvisorShares
Inception DateSep 15, 2021
Dividend Yield0.99%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume8,550
30 Day Avg. Volume16,628
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
57.06Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PSIL Summary
The AdvisorShares Psychedelics ETF (PSIL) is a fund that focuses on companies in the health care sector, specifically those involved in developing psychedelic-based treatments for mental health conditions like depression and PTSD. It includes innovative companies such as ATAI Life Sciences and Mind Medicine, which are leading research in this emerging field. Investors might consider PSIL for its potential growth as psychedelics gain acceptance in mainstream medicine. However, new investors should be aware that this ETF is highly specialized, meaning its performance can be volatile and heavily influenced by the success of the psychedelic drug industry.
How much will it cost me?The AdvisorShares Psychedelics ETF (PSIL) has an expense ratio of 0.99%, meaning you’ll pay $9.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized niche in the health care sector. Actively managed funds typically have higher costs due to the research and expertise involved in selecting investments.
What would affect this ETF?The AdvisorShares Psychedelics ETF (PSIL) could benefit from increasing acceptance of psychedelics in mainstream medicine and growing investment in mental health treatments, particularly for conditions like depression and PTSD. However, regulatory hurdles, slow drug approval processes, and potential shifts in public perception or government policies could negatively impact the sector’s growth. Global exposure and reliance on innovative but early-stage companies may add both opportunities and risks for investors.
PSIL Top 10 Holdings
The AdvisorShares Psychedelics ETF (PSIL) is deeply rooted in the health care sector, with a focus on innovative biotech and pharma companies exploring psychedelic treatments. Relmada Therapeutics is rising steadily, buoyed by pipeline developments, while VistaGen Therapeutics shows promising momentum despite financial hurdles. On the flip side, ATAI Life Sciences and Compass Pathways are lagging, weighed down by ongoing losses and operational challenges. The fund’s global exposure and concentration in clinical-stage firms make it a high-risk, high-reward play, with performance hinging on breakthroughs in mental health therapies.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ATAI Life Sciences | 11.42% | $2.21M | $1.56B | 215.44% | 47 Neutral | |
| COMPASS Pathways | 8.01% | $1.55M | $647.05M | 59.72% | 47 Neutral | |
| Relmada Therapeutics | 7.55% | $1.46M | $297.73M | 1006.27% | 41 Neutral | |
| Mind Medicine | 7.53% | $1.46M | $1.24B | 75.28% | 40 Neutral | |
| Supernus Pharmaceuticals | 7.23% | $1.40M | $2.70B | 30.38% | 55 Neutral | |
| Bright Minds Biosciences | 6.67% | $1.29M | C$902.21M | 98.53% | 48 Neutral | |
| Neurocrine | 5.66% | $1.10M | $15.24B | 20.60% | 80 Outperform | |
| Cybin | 5.52% | $1.07M | C$1.92M | -31.70% | 37 Underperform | |
| Alto Neuroscience, Inc. | 5.47% | $1.06M | $470.03M | 295.04% | 42 Neutral | |
| VistaGen Therapeutics | 5.38% | $1.04M | $167.86M | 74.90% | 48 Neutral |
PSIL Technical Analysis
Positive
―
Price Trends
19.14
Positive
18.19
Positive
15.50
Positive
Market Momentum
0.26
Negative
60.14
Neutral
94.35
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PSIL, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 18.53, equal to the 50-day MA of 19.14, and equal to the 200-day MA of 15.50, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 60.14 is Neutral, neither overbought nor oversold. The STOCH value of 94.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PSIL.
PSIL Peer Comparison
Comparison Results
Performance Comparison
PSIL
AdvisorShares Psychedelics ETF
19.81
9.27
87.95%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
GDOC
Goldman Sachs Future Health Care Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents